Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.41 USD
Change Today -0.04 / -2.76%
Volume 17.6K
ONTX On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

onconova therapeutics inc (ONTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $4.92
52 Week Low
11/19/15 - $1.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

onconova therapeutics inc (ONTX) Related Businessweek News

No Related Businessweek News Found

onconova therapeutics inc (ONTX) Details

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. Its clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, the company has various product candidates that target kinases, cellular metabolism, or cell division in preclinical development. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.

36 Employees
Last Reported Date: 11/12/15
Founded in 1998

onconova therapeutics inc (ONTX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $713.4K
Chief Financial Officer and Secretary
Total Annual Compensation: $347.9K
President of Research and Development
Total Annual Compensation: $450.7K
Senior Vice President of Product Development
Total Annual Compensation: $465.5K
Compensation as of Fiscal Year 2014.

onconova therapeutics inc (ONTX) Key Developments

Onconova Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Onconova Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, total net revenue was $1.6 million compared to $0.1 million last year. Revenues in the third quarter of 2015 primarily consisted of contractual cost sharing revenue from Baxalta for the INSPIRE trial. Loss from operations was $5.9 million against $14.9 million last year. Net loss attributable to Onconova Therapeutics, Inc. was $5.9 million or $0.26 per basic and diluted share against $14.9 million or $0.69 per basic and diluted share last year. For the nine months, total net revenue was $1.9 million compared to $0.7 million last year. Loss from operations was $27.2 million against $50.4 million last year. Net loss attributable to Onconova Therapeutics, Inc. was $27.2 million or $1.23 per basic and diluted share against $50.3 million or $2.32 per basic and diluted share last year.

Onconova Therapeutics Receives Non-Compliance Notice From NASDAQ

On September 29, 2015, Onconova Therapeutics, Inc. received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (NASDAQ) notifying the Company that for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (MVLS) had closed below the minimum $50,000,000 requirement for continued listing on The NASDAQ Global Select Market, set forth in NASDAQ Listing Rule 5450(b)(2)(A). The notice has no immediate effect on the listing of the Company’s common stock and the common stock will continue to trade on The NASDAQ Global Select Market under the symbol “ONTX” at this time. In accordance with NASDAQ Listing Rule 5810(c)(3)(C), the Company has a grace period of 180 calendar days, or until March 28, 2016, to regain compliance with NASDAQ Listing Rule 5450(b)(2)(A). Compliance can be achieved automatically and without further action if the Company’s MVLS closes at $50,000,000 or more for at least 10 consecutive business days at any time during the 180-day compliance period. If the Company does not regain compliance by March 28, 2016, NASDAQ will notify the Company that its common stock will be subject to delisting. The Company is currently considering available options to resolve the listing deficiency and to regain compliance. There can be no assurance that the Company will be able to regain compliance with The NASDAQ Global Select Market listing requirements. Another option available to the Company is to apply to transfer the listing of its common stock to The NASDAQ Capital Market. To qualify, the Company would need to satisfy the listing requirements for that market, which are lower than the requirements for The NASDAQ Global Select Market on which the common stock currently trades.

Onconova Therapeutics, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015

Onconova Therapeutics, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Presentation Date & Speakers: Nov-11-2015, Ramesh Kumar, Co-Founder, Chief Executive Officer, President and Director. Nov-12-2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTX:US $1.41 USD -0.04

ONTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.6x
Price/Book 10.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ONCONOVA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at